Dataset from Phase 3, Randomized, Double Blind, Placebo Controlled Study Of The Safety And Efficacy Of 2 Doses Of CP 690,550 In Patients With Active Rheumatoid Arthritis On Background DMARDS

This Phase 3 study is intended to provide evidence that CP-690,550 dosed 5 mg BID and 10 mg
BID is safe and effective when used in combination with a variety of traditional disease
modifying antirheumatic drugs in adult patients with rheumatoid arthritis. It is intended to
confirm the benefits of CP-690,550 in improving signs and symptoms and physical function that
were observed in the Phase 2 rheumatoid arthritis studies.